Edwards Lifesciences Corporation EW
95.19 USD +1.93 (+2.07%)
At closeNov 3, 2026, 6:40 PM EST
95.19 0.00 0.00%
After hours · Nov 3, 6:40 PM ET
93.27 Day range 96.09
74.66 52-week range 96.29
- YTD
- +11.66%
- 1 year
- +14.59%
Analyst view
Consensus: buy
Buy
Price target (mean) 101.87 +7.0% upside
Now 95.19
- Target (low)
- 84.00
- Target (mean)
- 101.87
- Target (high)
- 117.00
Ratings (0m) 30 23 buy · 7 hold · 0 sell
- Strong buy5
- Buy18
- Hold7
- Sell0
- Strong sell0
Recommendation trend
- This month 30
- 1 month ago 29
- 2 months ago 29
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.73653 | 0.72 – 0.77 | 0.67 | +9.9% | 1.68B | +8.0% | 24 |
| Next quarter | 0.7064 | 0.67 – 0.7626 | 0.58 | +21.8% | 1.70B | +8.3% | 24 |
| Current year | 3.00 | 2.96 – 3.05 | 2.56 | +17.2% | 6.76B | +11.4% | 29 |
| Next year | 3.38 | 3.29 – 3.50 | 3.00 | +12.7% | 7.43B | +9.9% | 29 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2026 | Barclays | Initiated | — | Overweight |
| Sep 11, 2026 | BTIG | Reiterated | Buy | Buy |
| Jul 24, 2026 | Leerink Partners | Upgrade | Market Perform | Outperform |
| Jul 24, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 24, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jul 16, 2026 | Truist Securities | Maintained | Hold | Hold |
| Jul 15, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jul 13, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 8, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jun 30, 2026 | BTIG | Maintained | Buy | Buy |
| Jun 16, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Jun 2, 2026 | TD Cowen | Maintained | Buy | Buy |
| Apr 27, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 24, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Apr 24, 2026 | Truist Securities | Maintained | Hold | Hold |
| Apr 24, 2026 | Canaccord Genuity | Maintained | Hold | Hold |
| Apr 24, 2026 | BTIG | Maintained | Buy | Buy |
| Apr 24, 2026 | Baird | Maintained | Neutral | Neutral |
| Apr 13, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Apr 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Feb 11, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Feb 11, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Feb 11, 2026 | Truist Securities | Maintained | Hold | Hold |
| Feb 11, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 11, 2026 | BTIG | Reiterated | Buy | Buy |
| Jan 20, 2026 | Stifel | Maintained | Buy | Buy |
| Jan 20, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Jan 12, 2026 | UBS | Maintained | Neutral | Neutral |
| Jan 12, 2026 | Barclays | Maintained | Overweight | Overweight |
